The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Buformin     2-butyl-1- (diaminomethylidene)guanidine

Synonyms: Glybigid, Biforon, Buformina, Buformine, Butformin, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Butylbiguanide


High impact information on Butylbiguanide

  • Buformin concentrations in serum, other body fluids and tissues were measured by gas chromatography [1].
  • Serum buformin concentration at admission was 5.5 mg/l. Postmortem concentrations were: in serum 3.2 mg/l; in lung 2.8 mg/kg wet weight; in heart 3.0 mg/kg; in pericardial fluid 3.5 mg/l; in liver 5.2 mg/kg; in bile 6.3 mg/l; and in kidney 98 mg/kg [1].
  • Effects of buformin on the metabolsim of the isolated haemoglobin-free perfused hindlimb of normal rats [5].
  • Furthermore, the extent of the increase in blood lactate caused by three different biguanides (metformin, buformin, and phenformin) was compared with the abilities to reduce oxygen consumption in isolated rat hepatocytes [6].
  • A comparison of these benzimidoylpyrazoles with classical standards (tolazamide, phenformin, and buformin) in several experimental models show that these compounds seem to combine in one molecule some of the biological activities of the beta-cytotrophic sulfonylureas and some of the activities of the biguanides [7].

Chemical compound and disease context of Butylbiguanide


Biological context of Butylbiguanide


Anatomical context of Butylbiguanide


Associations of Butylbiguanide with other chemical compounds


Gene context of Butylbiguanide


Analytical, diagnostic and therapeutic context of Butylbiguanide


  1. Buformin concentrations in a case of fatal lactic acidosis. Verdonck, L.F., Sangster, B., van Heijst, A.N., de Groot, G., Maes, R.A. Diabetologia (1981) [Pubmed]
  2. Treatment of reactive hypoglycemia with buformin. Sekso, M., Solter, M., Zjacić, V., Cabrijan, T. Am. J. Clin. Nutr. (1975) [Pubmed]
  3. Short-term effect of buformin, a biguanide, on insulin sensitivity, soluble fraction of tumor necrosis factor receptor and serum lipids in overweight patients with type 2 diabetes mellitus. Ohara, S., Komatsu, R., Matsuyama, T. Diabetes Res. Clin. Pract. (2004) [Pubmed]
  4. Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal. Kiho, T., Kato, M., Usui, S., Hirano, K. Clin. Chim. Acta (2005) [Pubmed]
  5. Effects of buformin on the metabolsim of the isolated haemoglobin-free perfused hindlimb of normal rats. Strohfeldt, P., Kettl, H., Obermaier, U., Weinges, K.F. Diabetologia (1975) [Pubmed]
  6. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Wang, D.S., Kusuhara, H., Kato, Y., Jonker, J.W., Schinkel, A.H., Sugiyama, Y. Mol. Pharmacol. (2003) [Pubmed]
  7. Chemistry and hypoglycemic activity of benzimidoylpyrazoles. Shroff, J.R., Bandurco, V., Desai, R., Kobrin, S., Cervoni, P. J. Med. Chem. (1981) [Pubmed]
  8. Factors influencing absorption and excretion of drugs. VI. Effect of sodium cholate on in situ rat intestinal absorption of buformin. Kojima, S., Hamada, C., Tanaka, R. Chem. Pharm. Bull. (1977) [Pubmed]
  9. Effect of buformin on muscle energy metabolism. Strohfeldt, P., Strubel, U. Horm. Metab. Res. (1976) [Pubmed]
  10. Effect of buformin on splanchnic carbohydrate and substrate metabolism in healthy man. Bratusch-Marrain, P.R., Korn, A., Waldhäusl, W.K., Gasić, S., Nowotny, P. Metab. Clin. Exp. (1981) [Pubmed]
  11. The inhibitory action of buformin, a biguanide on gluconeogenesis from alanine and its transport system in rat livers. Hotta, N., Komori, T., Kobayashi, M., Sakakibara, F., Koh, N., Sakamoto, N. Diabetes Res. Clin. Pract. (1993) [Pubmed]
  12. Effect of buformin on the regulation of glycogen metabolism in the skeletal muscle of normal rats. Strohfeldt, P., Strubel-Obermaier, U., Kettl, H. Arzneimittel-Forschung. (1977) [Pubmed]
  13. Oral versus intravenous administration of butylbiguanide: effect on oral glucose tolerance in normal humans. Berger, E.G., Moehr, P. Eur. J. Clin. Invest. (1976) [Pubmed]
  14. Acrylic microspheres for oral controlled release of the biguanide buformin. Fundueanu, G., Mocanu, G., Constantin, M., Carpov, A., Bulacovschi, V., Esposito, E., Nastruzzi, C. International journal of pharmaceutics. (2001) [Pubmed]
  15. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Yasuda, N., Inoue, T., Nagakura, T., Yamazaki, K., Kira, K., Saeki, T., Tanaka, I. Biochem. Biophys. Res. Commun. (2002) [Pubmed]
  16. Buformin suppresses the expression of glyceraldehyde 3-phosphate dehydrogenase. Yano, A., Kubota, M., Iguchi, K., Usui, S., Hirano, K. Biol. Pharm. Bull. (2006) [Pubmed]
  17. A validated HPLC method with ultraviolet detection for the determination of buformin in plasma. Chou, C.H., Cheng, C.L., Huang, C.C. Biomed. Chromatogr. (2004) [Pubmed]
  18. RAdioimmunoassay of n-butylbiguanide. Otting, F. Meth. Enzymol. (1982) [Pubmed]
  19. A case of acromegaly improved by pituitary apoplexy. Abe, K., Hirata, Y. Endocrinol. Jpn. (1975) [Pubmed]
  20. Metabolic effects of buformin on the isolated perfused rat hindlimb during electrical stimulation. Strohfeldt, P., Strubel-Obermaier, U. Pharmacological research communications. (1977) [Pubmed]
WikiGenes - Universities